SCHEMBL5401437

SCHEMBL5401437

O=S(=O)(Nc1nnc(-c2ccccc2)s1)c1ccc(Oc2ccccc2)cc1

nearest known ligand 0.71

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 3/20 0.71
MEN1 O00255 1/20 0.71
ALOX12 P18054 1/20 0.71
HTT P42858 1/20 0.71
KMT2A Q03164 1/20 0.71
CA1 P00915 3/20 0.57
CA2 P00918 2/20 0.57
CA5A P35218 2/20 0.57
CA5B Q9Y2D0 2/20 0.57
CA4 P22748 1/20 0.57
USP2 O75604 2/20 0.53
USP8 P40818 2/20 0.53
PGR P06401 3/20 0.52
KDM4E B2RXH2 2/20 0.52
ALDH1A1 P00352 4/20 0.52
GGT1 P19440 1/20 0.52
HPGD P15428 2/20 0.51
PKM P14618 1/20 0.51
FFAR1 O14842 2/20 0.50
CA12 O43570 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5830937 0.87 MEN1 (0.81) LMNAMEN1ALOX12HTTKMT2A
SCHEMBL634004 0.83 MEN1 (0.75) LMNAMEN1ALOX12HTTKMT2A
SCHEMBL2177851 0.83 LMNA (0.75) LMNAMEN1ALOX12HTTKMT2A
SCHEMBL5386848 0.83 LMNA (0.75) LMNAMEN1ALOX12HTTKMT2A
SCHEMBL5409878 0.81 LMNA (0.67) LMNAMEN1ALOX12HTTKMT2A
SCHEMBL5401423 0.81 ALDH1A1 (0.75) LMNAHTTCA1PGRKDM4E
SCHEMBL2197860 0.80 MEN1 (0.70) LMNAMEN1ALOX12HTTKMT2A
SCHEMBL5830757 0.79 MEN1 (0.68) LMNAMEN1ALOX12HTTKMT2A
SCHEMBL634365 0.77 MEN1 (0.62) LMNAMEN1ALOX12HTTKMT2A
SCHEMBL5831181 0.76 MEN1 (0.64) LMNAMEN1ALOX12HTTKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070066614-A1 Ihibitors of 11-beta-hydroxy steroid dehydrogenase type 1 BIOVITRUM AB 2007-03-22 US claimed
US-7173030-B2 Inhibitors of 11-β-hydroxy steroid dehydrogenase type 1 BIOVITRUM AB (SE) 2007-02-06 US claimed
EP-1631558-A1 INHIBITORS OF 11-BETA-HYDROXY STEROID DEHYDROGENASE TYPE I BIOVITRUM AB (SE) 2006-03-08 EP claimed
US-20050009821-A1 Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1 BIOVITRUM AB 2005-01-13 US claimed
WO-2004103980-A1 INHIBITORS OF 11-BETA-HYDROXY STEROID DEHYDROGENASE TYPE I BIOVITRUM AB (SE) 2004-12-02 WO claimed
US-20070066614-A1 Ihibitors of 11-beta-hydroxy steroid dehydrogenase type 1 BIOVITRUM AB 2007-03-22 US disclosed
US-7173030-B2 Inhibitors of 11-β-hydroxy steroid dehydrogenase type 1 BIOVITRUM AB (SE) 2007-02-06 US disclosed
EP-1631558-A1 INHIBITORS OF 11-BETA-HYDROXY STEROID DEHYDROGENASE TYPE I BIOVITRUM AB (SE) 2006-03-08 EP disclosed
US-20050009821-A1 Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1 BIOVITRUM AB 2005-01-13 US disclosed
WO-2004103980-A1 INHIBITORS OF 11-BETA-HYDROXY STEROID DEHYDROGENASE TYPE I BIOVITRUM AB (SE) 2004-12-02 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050009821-A1 Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1 HSD11B1, HSD17B1, HSD11B2 LMNA 2030/4885MEN1 942/4885ALOX12 366/4885
US-20070066614-A1 Ihibitors of 11-beta-hydroxy steroid dehydrogenase type 1 HSD11B1, HSD17B1, HSD17B11 LMNA 1581/4885MEN1 974/4885ALOX12 736/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.